Table of Contents
ISRN Ophthalmology
Volume 2012, Article ID 480212, 9 pages
http://dx.doi.org/10.5402/2012/480212
Review Article

Today and Future of Age-Related Macular Degeneration

Department of Ophthalmology, Kunming General Hospital of PLA, Yunnan, Kunming 650038, China

Received 27 December 2011; Accepted 29 January 2012

Academic Editors: H. Ahmadieh, B. Bui, A. Kakehashi, and W. H. Seiple

Copyright © 2012 Kang Liu and Bolin Xie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. M. Gehrs, D. H. Anderson, L. V. Johnson, and G. S. Hageman, “Age-related macular degeneration—emerging pathogenetic and therapeutic concepts,” Annals of Medicine, vol. 38, no. 7, pp. 450–471, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. H. Rosa, B. M. Glaser, Z. De la Cruz, and W. R. Green, “Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-β2, and gas tamponade,” American Journal of Ophthalmology, vol. 122, no. 6, pp. 853–863, 1996. View at Google Scholar · View at Scopus
  3. W. R. Green, “Histopathology of age-related macular degeneration,” Molecular Vision, vol. 5, p. 27, 1999. View at Google Scholar · View at Scopus
  4. P. E. Rakoczy, S. H. Sarks, N. Daw, and I. J. Constable, “Distribution of cathepsin D in human eyes with or without age-related maculopathy,” Experimental Eye Research, vol. 69, no. 4, pp. 367–374, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. Sarks, J. J. Arnold, M. C. Killingsworth, and J. P. Sarks, “Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study,” British Journal of Ophthalmology, vol. 83, no. 3, pp. 358–368, 1999. View at Google Scholar · View at Scopus
  6. J. L. Haines, N. Schnetz-Boutaud, S. Schmidt et al., “Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6,” Investigative Ophthalmology and Visual Science, vol. 47, no. 1, pp. 329–335, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. K. U. Loffler and W. R. Lee, “Basal linear deposit in the human macula,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 224, no. 6, pp. 493–501, 1986. View at Publisher · View at Google Scholar · View at Scopus
  8. G. E. Marshall, A. G. P. Konstas, G. G. Reid, J. G. Edwards, and W. R. Lee, “Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula,” British Journal of Ophthalmology, vol. 76, no. 10, pp. 607–614, 1992. View at Google Scholar · View at Scopus
  9. T. L. Van der Schaft, C. M. Mooy, W. C. De Bruijn, and P. T. V. M. de Jong, “Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study,” British Journal of Ophthalmology, vol. 77, no. 10, pp. 657–661, 1993. View at Google Scholar · View at Scopus
  10. S. H. Sarks, “Ageing and degeneration in the macular region: a clinico pathological study,” British Journal of Ophthalmology, vol. 60, no. 5, pp. 324–341, 1976. View at Google Scholar · View at Scopus
  11. W. R. Green and C. Enger, “Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman lecture,” Ophthalmology, vol. 100, no. 10, pp. 1519–1535, 1993. View at Google Scholar · View at Scopus
  12. C. W. Spraul, G. E. Lang, H. E. Grossniklaus, and G. K. Lang, “Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes,” Survey of Ophthalmology, vol. 44, no. 2, pp. S10–S32, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Sarks, S. Cherepanoff, M. Killingsworth, and J. Sarks, “Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration,” Investigative Ophthalmology and Visual Science, vol. 48, no. 3, pp. 968–977, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. R. T. Smith, M. A. Sohrab, N. Pumariega et al., “Dynamic soft drusen remodelling in age-related macular degeneration,” British Journal of Ophthalmology, vol. 94, no. 12, pp. 1618–1623, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. G. S. Hageman, P. J. Luthert, N. H. Victor Chong, L. V. Johnson, D. H. Anderson, and R. F. Mullins, “An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration,” Progress in Retinal and Eye Research, vol. 20, no. 6, pp. 705–732, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. J. W. Crabb, M. Miyagi, X. Gu et al., “Drusen proteome analysis: an approach to the etiology of age-related macular degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14682–14687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. R. F. Mullins, S. R. Russell, D. H. Anderson, and G. S. Hageman, “Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease,” FASEB Journal, vol. 14, no. 7, pp. 835–846, 2000. View at Google Scholar · View at Scopus
  18. H. Chen, B. Liu, T. J. Lukas, and A. H. Neufeld, “The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration,” PLoS ONE, vol. 3, no. 6, Article ID e2339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Wang, V. M. Wang, and C. C. Chan, “The role of anti-inflammatory agents in age-related macular degeneration (amd) treatment,” Eye, vol. 25, no. 2, pp. 127–139, 2011. View at Google Scholar
  20. P. T.V.M. De Jong, “Age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1474–1485, 2006. View at Publisher · View at Google Scholar
  21. R. Brancato, U. Introini, L. Pierro et al., “Optical coherence tomography (OCT) in retinal angiomatous proliferation (RAP),” European Journal of Ophthalmology, vol. 12, no. 6, pp. 467–472, 2002. View at Google Scholar · View at Scopus
  22. M. C. Donati, G. Carifi, G. Virgili, and U. Menchini, “Retinal angiomatous proliferation: association with clinical and angiographic features,” Ophthalmologica, vol. 220, no. 1, pp. 31–36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. A. Hunter, M. T. Dunbar, and P. J. Rosenfeld, “Retinal angiomatous proliferation: clinical characteristics and treatment options,” Optometry, vol. 75, no. 9, pp. 577–588, 2004. View at Google Scholar · View at Scopus
  24. X. Ding, M. Patel, and C. C. Chan, “Molecular pathology of age-related macular degeneration,” Progress in Retinal and Eye Research, vol. 28, no. 1, pp. 1–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Zareparsi, K. E. H. Branham, M. Li et al., “Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration,” American Journal of Human Genetics, vol. 77, no. 1, pp. 149–153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. P. Conley, A. Thalamuthu, J. Jakobsdottir et al., “Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy,” Human Molecular Genetics, vol. 14, no. 14, pp. 1991–2002, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. D. F. Conrad, D. Pinto, R. Redon et al., “Origins and functional impact of copy number variation in the human genome,” Nature, vol. 464, no. 7289, pp. 704–712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Ahuja, J. D. Benner, J. C. Schwartz, J. W. Butler, and S. M. Steidl, “Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration,” Seminars in Ophthalmology, vol. 16, no. 2, pp. 81–85, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. A. Zarbin, “Current concepts in the pathogenesis of age-related macular degeneration,” Archives of Ophthalmology, vol. 122, no. 4, pp. 598–614, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Kent and C. Sheridan, “Choroidal neovascularization: a wound healing perspective,” Molecular Vision, vol. 9, pp. 747–755, 2003. View at Google Scholar · View at Scopus
  31. J. Bradley, M. Ju, and G. S. Robinson, “Combination therapy for the treatment of ocular neovascularization,” Angiogenesis, vol. 10, no. 2, pp. 141–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan, “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1287–1295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Yang, J. Hu, J. Zhang, and H. Guan, “Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese,” British Journal of Ophthalmology, vol. 94, no. 9, pp. 1211–1214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Kassoff, J. Kassoff, J. Buehler et al., “A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8,” Archives of Ophthalmology, vol. 119, no. 10, pp. 1417–1436, 2001. View at Google Scholar · View at Scopus
  35. J. M. Seddon, J. Cote, and B. Rosner, “Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake,” Archives of Ophthalmology, vol. 121, no. 12, pp. 1728–1737, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ip, A. Kroll, and E. Reichel, “Transpupillary thermotherapy,” Seminars in Ophthalmology, vol. 14, no. 1, pp. 11–18, 1999. View at Google Scholar · View at Scopus
  37. E. Reichel, A. M. Berrocal, M. Ip et al., “Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration,” Ophthalmology, vol. 106, no. 10, pp. 1908–1914, 1999. View at Google Scholar · View at Scopus
  38. A. A. Hussain, Y. Lee, J. J. Zhang, and J. Marshall, “Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 52, no. 7, pp. 4459–4466, 2011. View at Google Scholar
  39. R. S. B. Newsom, J. C. McAlister, M. Saeed, and J. D. A. McHugh, “Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation,” British Journal of Ophthalmology, vol. 85, no. 2, pp. 173–178, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Yu, T. R. Bhangale, J. Fagerness et al., “Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration,” Human Molecular Genetics, vol. 20, no. 18, pp. 3699–3709, 2011. View at Publisher · View at Google Scholar
  41. X. Liu, P. Zhao, S. Tang et al., “Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population,” Retina, vol. 30, no. 8, pp. 1177–1184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Dong, Y. Qu, H. Jiang et al., “Correlation of complement factor H gene polymorphisms with exudative age-related macular degeneration in a Chinese cohort,” Neuroscience Letters, vol. 488, no. 3, pp. 283–287, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Vojniković, S. Synek, V. Mićović, M. Teležar, and Z. Linšak, “Epidemiological study of sun exposure and visual field damage in children in Primorsko-Goranska County—the risk factors of earlier development of macular degeneration,” Collegium Antropologicum, vol. 34, supplement 2, pp. 57–59, 2010. View at Google Scholar
  44. F. Jonasson, A. Arnarsson, H. Sasaki, T. Peto, K. Sasaki, and A. C. Bird, “The prevalence of age-related maculopathy in Iceland: reykjavik eye study,” Archives of Ophthalmology, vol. 121, no. 3, pp. 379–385, 2003. View at Google Scholar · View at Scopus
  45. A. Ostenfeld-Åkerblom, “Age-related macular degeneration in Inuit,” Acta Ophthalmologica Scandinavica, vol. 77, no. 1, pp. 76–78, 1999. View at Google Scholar · View at Scopus
  46. P. Mitchell, W. Smith, K. Attebo, and Jie Jin Wang, “Prevalence of age-related maculopathy in Australia: the blue mountains eye study,” Ophthalmology, vol. 102, no. 10, pp. 1450–1460, 1995. View at Google Scholar · View at Scopus
  47. L. Xu, S. Wang, Y. Li, and J. B. Jonas, “Retinal vascular abnormalities and prevalence of age-related macular degeneration in adult Chinese: the Beijing Eye study,” American Journal of Ophthalmology, vol. 142, no. 4, pp. 688–689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Synek, B. Vojniković, and D. Pahor, “Epidemiology and quality of life of patients with age-related macular degeneration,” Collegium Antropologicum, vol. 34, supplement 2, pp. 25–28, 2010. View at Google Scholar
  49. B. Muñoz, R. Klein, J. Rodriguez, R. Snyder, and S. K. West, “Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: proyecto VER,” Archives of Ophthalmology, vol. 123, no. 11, pp. 1575–1580, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Muñoz, R. Klein, J. Rodriguez, R. Snyder, and S. K. West, “Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: proyecto VER,” Archives of Ophthalmology, vol. 123, no. 11, pp. 1575–1580, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. U. Chakravarthy, T. Y. Wong, A. Fletcher et al., “Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis,” BMC Ophthalmology, vol. 10, no. 1, article 31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. R. D. Sperduto, L. A. Yannuzzi, J. A. Sorenson et al., “Risk factors for neovascular age-related macular degeneration,” Archives of Ophthalmology, vol. 110, no. 12, pp. 1701–1708, 1992. View at Google Scholar
  53. A. F. Cruess, G. Zlateva, A. M. Pleil, and B. Wirostko, “Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties,” Acta Ophthalmologica, vol. 87, no. 2, pp. 118–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Mataix, M. Carmen Desco, E. Palacios, M. Garcia-Pous, and A. Navea, “Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study,” Ophthalmic Surgery Lasers and Imaging, vol. 40, no. 3, pp. 277–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Sonmez, P. A. Sonmez, S. S. Ozkan, and L. S. Atmaca, “One-year outcomes of less frequent bevacizumab in age-related macular degeneration,” Retina, vol. 31, no. 4, pp. 645–653, 2011. View at Publisher · View at Google Scholar
  56. K. D. Kovacs, M. T. Quirk, T. Kinoshita et al., “A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration,” Retina, vol. 31, no. 3, pp. 446–452, 2011. View at Publisher · View at Google Scholar
  57. J. B. Jonas, Y. Tao, and F. C. Schlichtenbrede, “Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 5, pp. 467–470, 2011. View at Publisher · View at Google Scholar
  58. C. Trempe, “Ranibizumab for age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 6, pp. 581–582, 2011. View at Google Scholar
  59. T. L. Sãrensen and H. Kemp, “Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision,” Acta Ophthalmologica, vol. 89, no. 1, p. e97, 2011. View at Publisher · View at Google Scholar
  60. C. Schmucker, Y. K. Loke, C. Ehlken et al., “Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review,” British Journal of Ophthalmology, vol. 95, 308 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Chiang and C. D. Regillo, “Preferred therapies for neovascular age-related macular degeneration,” Current Opinion in Ophthalmology, vol. 22, no. 3, pp. 199–204, 2011. View at Publisher · View at Google Scholar
  62. M. H. Berrocal, M. L. Lewis, and H. W. Flynn, “Variations in the clinical course of submacular hemorrhage,” American Journal of Ophthalmology, vol. 122, no. 4, pp. 486–493, 1996. View at Google Scholar · View at Scopus
  63. J. L. Borrillo and C. D. Regillo, “Treatment of subretinal hemorrhages with tissue plasminogen activator,” Current Opinion in Ophthalmology, vol. 12, no. 3, pp. 207–211, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. C. I. Falkner, H. Leitich, F. Frommlet, P. Bauer, and S. Binder, “The end of submacular surgery for age-related macular degeneration? A meta-analysis,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 4, pp. 490–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. P. V. Algvere and S. Seregard, “Age-related maculopathy: pathogenetic features and new treatment modalities,” Acta Ophthalmologica Scandinavica, vol. 80, no. 2, pp. 136–143, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. P. A. Campochiaro, “Retinal and choroidal neovascularization,” Journal of Cellular Physiology, vol. 184, no. 3, pp. 301–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. N. S. Dejneka, A. Auricchio, A. M. Maguire et al., “Pharmacologically regulated gene expression in the retina following transduction with viral vectors,” Gene Therapy, vol. 8, no. 6, pp. 442–446, 2001. View at Publisher · View at Google Scholar · View at Scopus
  68. D. W. Dawson, O. V. Volpert, P. Gillis et al., “Pigment epithelium-derived factor: a potent inhibitor of angiogenesis,” Science, vol. 285, no. 5425, pp. 245–248, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. N. M. Holekamp, N. Bouck, and O. Volpert, “Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration,” American Journal of Ophthalmology, vol. 134, no. 2, pp. 220–227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. E. J. Duh, H. S. Yang, I. Suzuma et al., “Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth,” Investigative Ophthalmology and Visual Science, vol. 43, no. 3, pp. 821–829, 2002. View at Google Scholar · View at Scopus
  71. T. K. MacLachlan, M. Lukason, M. Collins et al., “Preclinical safety evaluation of AAV2-sFLT01- A gene therapy for age-related macular degeneration,” Molecular Therapy, vol. 19, no. 2, pp. 326–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Honda, T. Sakamoto, T. Ishibashi, H. Inomata, and H. Ueno, “Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration,” Gene Therapy, vol. 7, no. 11, pp. 978–985, 2000. View at Google Scholar · View at Scopus
  73. H. L. Kong, D. Hecht, W. Song et al., “Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor,” Human Gene Therapy, vol. 9, no. 6, pp. 823–833, 1998. View at Google Scholar · View at Scopus